Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Schrodinger price target raised to $28 from $27 at Goldman Sachs
05:17pm, Wednesday, 13'th Nov 2024
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving b
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Wednesday, 13'th Nov 2024
Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall S
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
10:36am, Wednesday, 13'th Nov 2024
Novartis (NVS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
5 Low-Leverage Stocks to Buy Amid the Focus on Inflation Data
09:45am, Wednesday, 13'th Nov 2024
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy JHG, CCB, NVS, APOG and IDCC.
Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion
07:39am, Tuesday, 12'th Nov 2024
Schrödinger will receive $150 million upfront plus up to $2.3 billion in milestone and royalty payments.
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
06:45am, Tuesday, 12'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
NVS or LLY: Which Is the Better Value Stock Right Now?
12:45pm, Monday, 11'th Nov 2024
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two companies is the best option for those look
Is Novartis (NVS) Stock Undervalued Right Now?
10:45am, Tuesday, 05'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
05:38am, Saturday, 02'nd Nov 2024
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
03:12pm, Wednesday, 30'th Oct 2024
On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 30'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis: It's Not Too Late To Buy This Dividend Stock Now
07:00am, Wednesday, 30'th Oct 2024
Since my previous article in May, shares of Novartis AG have gone on to outperform the S&P 500 index. The drugmaker's revenue and core EPS topped analysts' expectations in Q3. Novartis' debt load rema
Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO
04:10am, Wednesday, 30'th Oct 2024
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
05:05pm, Tuesday, 29'th Oct 2024
Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth but investor disappointment stemmed from a revenue adjustm
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
03:03pm, Tuesday, 29'th Oct 2024
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial
